

1 **Off-label use in Palliative Care – more common**
2 **than expected. A retrospective chart review**

3 Vera Hagemann¹

4 Claudia Bausewein PhD¹

5 Constanze Rémi MSc^{1,2}

6 1 Department of Palliative Medicine, Munich University Hospital, Ludwig-Maximilians-
7 University Munich, Germany

8 2 Hospital Pharmacy, Munich University Hospital, Ludwig-Maximilians-University
9 Munich, Germany

10

11 Corresponding author:

12 Constanze Rémi MSc

13 Department of Palliative Medicine and Hospital Pharmacy

14 Munich University Hospital

15 Marchioninstr. 15

16 81377 München, Germany

17 Phone: +49(0)89 4400 74962

18 Fax: +49(089) 4400 77921

19 Email: constanze.remi@med.uni-muenchen.de

20 Orcid ID 0000-0001-7655-0306

21 **Keywords** palliative care, off-label use, evidence-based medicine, quality of health
22 care, safety

23 **Word count:** 3035

24 **Reference count:** 24

25 **Abstract**

26 **Objective**

27 Off-label drug use seems to be integral to palliative care pharmacotherapy. Balancing
28 potential risks and benefits in the context of limited therapeutic options is challenging.
29 To provide specific support for clinicians in dealing with off-label use, it is essential to
30 understand off-label use in everyday clinical practice.

31 The aim of this pilot study was to quantify and describe off-label use in a palliative
32 care unit.

33 **Methods**

34 Retrospective chart review of all adult patients treated on a palliative care unit in
35 10/2017. All data on drug use e.g. indication, dose, route of administration were
36 extracted and matched with the prescribing information. Identified off-label use was
37 subsequently compared with recommendations in the relevant literature. The main
38 outcome measure was frequency and type of off-label drug use.

39 **Results**

40 2,352 drug application days (d) and 93 drugs were identified for 28 patients. Of all
41 drugs, 47 (51%) were used off-label at least once. Most off-label uses concerned
42 indication (57%), followed by mode of administration. In drugs highly relevant to
43 palliative care the rate of off-label use was as high as 67%. The extent to which off-
44 label therapy was supported by literature was very variable and ranged from 0 to
45 88%.

46 **Conclusions**

47 This single-unit data confirms the high prevalence of off-label use in palliative
48 medicine and demonstrates that off-label use in palliative care is very multifaceted.
49 The data presented allows for a more precise characterization of various aspects of
50 off-label use in order to derive concrete further measures for research and clinical
51 practice.

52

53

54

55 **What is already known on this subject**

- 56 • Off-label drug use is likely to be common in palliative care, but detailed data is
57 very limited
- 58 • Off-label drug use is a potential threat for patient safety
- 59 • Physicians state to make therapeutic decisions based on their own experience,
60 due to a lack of available evidence and lack of support in assessment

61 **What this study adds**

- 62 • off-label use in palliative care is multifaceted
- 63 • the mode of administration (e.g. combination with other drugs in a syringe
64 driver) is beside indication a common reasons for off label use
- 65 • the proportion of off-label use without sound evidence is high.

66

67 Introduction

68 The aim of palliative care is to improve quality of life of patients with advanced
69 diseases. Drug therapy is a mainstay in the treatment of physical symptoms.
70 However, based on the few data available so far, it can be assumed that up to a
71 quarter of all prescribed drugs are used outside the scope of the marketing
72 authorization in palliative care¹⁻⁴. In general, "off-label use" refers to all deviations
73 from the approval (license) of the drug, for example with regard to indication, route of
74 administration, dosage interval or duration of treatment^{5, 6}.

75 In contrast to other medical disciplines, the management of patients towards the end
76 of life does not focus on curative or disease-modifying treatment approaches but on
77 the alleviation of distressing symptoms. Often, only the route of administration or
78 dosage differs from the manufacturer's approval. The existing evidence for off-label
79 use in palliative medicine is very heterogeneous, e.g. with good evidence for the use
80 of opioids for breathlessness⁷ but only very limited evidence with case reports and
81 small studies on the frequent practice of subcutaneous infusion of midazolam (e.g.^{8,}
82 ⁹).

83 Off-label use involves both medical and legal challenges. It always carries the
84 potential risk of a drug that has not been tested or insufficiently tested for its intended
85 use and thus is a potential threat for patient safety¹⁰. Additionally, off-label use can
86 lead to limited coverage of treatment costs by insurance companies or changes in
87 liability for treatment related harm¹¹.

88 Accordingly, it should be applied consciously and well-considered. In clinical practice,
89 however, there is often a lack of time and resources to conduct a patient-specific risk-
90 benefit analysis for each therapy on the basis of the current literature and available
91 alternatives¹. Achieving the Hippocratic principle of "Primum non nocere" ("first, do
92 no harm") is therefore often a major challenge. Physicians regularly make therapeutic
93 decisions based on their own experience, especially due to lack of available evidence
94 and lack of support in assessment¹¹. They express concerns about the safety of drug
95 therapy¹¹. To date, there are only limited data to provide a sound evidence-base for
96 decision-making on the use of drugs in palliative medicine. In addition, such studies
97 are difficult to conduct due to methodological difficulties. Pharmacists can play an
98 important role in the off-label medication process. Potential tasks include:

99 identification of off-label therapies, assisting in the interpretation of the available
100 evidence, evaluation of possible treatment alternatives and support in the patient-
101 specific benefit-risk assessment¹².

102 For providing specific support for clinicians in dealing with off-label use, it is essential
103 to understand off-label use in everyday clinical practice. This includes not only the
104 prevalence but also the clinical circumstances, the underlying evidence and the
105 decision-making processes. Based on this knowledge it is only possible to decide
106 whether measures should be taken to increase safety of therapy and make it possibly
107 more effective for the patient. At the same time, however, such measures can also
108 help to give prescribers more security in dealing with off-label use.

109 As little is known about off-label use in palliative medicine in Germany and
110 internationally^{1, 11}, the aim of this pilot study was to quantify and describe off-label
111 use in adult patients treated on a palliative care unit.

112

113 **Methods**

114 Medical charts of patients treated in the palliative care unit of the Department of
115 Palliative Medicine at Munich University Hospital between 1st and 31st October 2017
116 were retrospectively reviewed. The reporting of this chart review complies with the
117 STROBE criteria for reporting cross-sectional studies¹³.

118

119 The palliative care unit at Munich University Hospital provides acute palliative care
120 for patients with advanced disease. Annually, about 300 patients are treated in the
121 unit (286 in 2017) of which about 40% are discharged. Patients suffer predominantly
122 from malignant (about 75%) and non-malignant disease.

123 Prescribing data was extracted for all drugs administered on the unit during October
124 2017 using an extraction sheet. This month was randomly selected from all months
125 of the year with typical patient case numbers for the unit. The extraction sheet was
126 piloted by two persons and subsequently modified. Data was extracted by two
127 pharmacy students and data integrity randomly checked by two pharmacists. The
128 recording encompassed active generic drug, trade name, indication, dose, dosing

129 interval, route of administration, mode of administration, and duration of therapy.
 130 Drug applications were recorded as application days, i.e. every day on which a drug
 131 was administered per patient and not every single dose was counted. This was to
 132 avoid bias due to short rather than long dosing intervals. The data obtained was
 133 compared with the prescribing information to identify off-label applications. An
 134 application day was rated as off-label when a drug was applied for an aspect outside
 135 the scope of the marketing authorisation regarding indication, drug dose, dosing
 136 interval, route of administration, mode of administration (e.g. crushed, via feeding
 137 tube, combination with other drugs in syringe driver, continuous infusion), and
 138 duration of therapy (s. table 1). This was also the case if, for example, morphine was
 139 used in an approved indication (pain) but mixed with other substances in the same
 140 infusion for administration. Off-label use was subsequently compared with
 141 recommendations in the German Guideline on Palliative Medicine for Patients with
 142 Incurable Cancer¹⁴ and the German Palliative Care Formulary¹⁵ in order to identify
 143 drug uses outside the scope of the marketing authorisation but within the range of
 144 official or accepted therapy recommendations.

145

Off-label use type	explanation	example
indication	use for an non-labelled indication	morphine for dyspnea
dose	use of a higher or lower dose than licensed	citalopram 40mg/d for a patient >65 years
dosing interval	administration of a drug in a shorter or longer dosing interval than approved	daily change of a fentanyl patch
route of administration	administration via a non licensed route	midazolam subcutaneously
mode of administration	deviations from the approved mode of administration	continuous infusion of levetiracetam
duration of therapy	deviations from the authorized duration of therapy	use of metoclopramide for 10 days
dose titration	a different dose-titration regimen compared to the marketing	increasing the pregabalin dose every other day

146 Tab.1 Off-label use types with explanations and examples from palliative care
147 practice

148

149 In addition, the following patient data were recorded anonymously: age, disease
150 (malignant/non-malignant) and sex.

151 The evaluation of ambiguous prescriptions was discussed between two pharmacists,
152 for example several or unclear indications of a drug.

153 A committee consisting of two pharmacists and a doctor additionally divided the
154 identified drugs into three categories based on their relevance in symptom control in
155 palliative medicine: 1. high relevance, 2. medium relevance, 3. low relevance.

156 Drugs in the first group (high relevance) included those typically used in symptom
157 control in palliative medicine based on published data and personal experience^{14, 16,}
158 ¹⁷, e.g. opioids, non-opioid analgesics, antiemetics, antipsychotics, benzodiazepines,
159 antidepressants, antiepileptics, laxatives, anticholinergics and ketamine. Drugs with
160 medium relevance were those used relatively regularly to prevent complications (e.g.
161 anticoagulants, levothyroxine) but were not prescribed for distressing symptoms. In
162 addition, drugs with medium relevance were also those used less frequently (e.g.
163 bisphosphonates, drugs for Parkinson's disease) or for a questionable indication, e.g.
164 proton pump inhibitors and various drugs for insomnia.

165 Drugs considered to be of low relevance were generally those used for comorbidities
166 with no or little impact on current distressing symptoms, e.g. antihypertensives,
167 antidiabetics.

168 Descriptive statistics (frequencies and percentages) were calculated to describe and
169 summarize all variables using Microsoft excel (version 1902).

170 The Research Ethics Committee of the Ludwig-Maximilians-Universität Munich
171 granted ethical approval for this study (19-445).

172 **Results**

173 The chart review identified a total of 2,352 drug application days (d). Over the period
 174 of one month, 93 different drugs were administered to 28 patients (15 males; 54%)
 175 with a median age of 74 years (range 41-95) on 284 patient days. All but four
 176 patients suffered from malignant disease. Of all drugs, 47 (51%) were used off-label
 177 at least once.

178 Of 2,352 application days, 1,248 days (53%) were off-label. Most off-label uses
 179 concerned the indication (56.5%), followed by mode of administration, drug dose,
 180 and route of administration (see Fig.1).

181

182 Figure 1 about here

183

184 The drugs identified were pooled in 19 groups (Tab. 2), according to their
 185 pharmacologic group or target symptom. The grouping was decided after discussion
 186 in the research team. It should be noted that some drugs could appear in more than
 187 one group if there was more than one indication or the indication remained unclear,
 188 e.g. melperone and levomepromazine as antipsychotics and hypnotics.

Drug group	Off-label (%)	Application days	In-label (d)	Off-label (d)
Anaesthetics^a	100.0%	17	0	17
Antipsychotics	89.5%	95	10	85
Antidepressants	84.3%	153	24	129
GIT-symptoms^b	73.1%	186	50	136
Corticosteroids	71.0%	148	43	105
Opioids	70.4%	328	97	231
Benzodiazepine	69.8%	96	29	67
Hypnotics	65.4%	228	79	149
Antiemetics	63.1%	195	72	123
Respiratory tract^c	46.0%	224	121	103
Diuretics	45.8%	72	39	33
Anti-infectives	38.1%	42	26	16
Other	34.8%	178	116	62

Non-opioid analgesics	29.8%	188	132	56
Anticoagulation	18.6%	102	83	19
Antiepileptics	17.8%	174	143	31
Laxatives	0%	130	130	0
Cytostatics	0%	13	13	0
Bone metabolism	0%	21	21	0

189 Tab.2 Drug groups used during the study period (descending order of off-label use
190 frequency)

191 ^aKetamine only drug in group

192 ^bDrugs for gastrointestinal symptoms (not antiemetics): esomeprazole, hyoscine butylbromide,
193 magaldrat, pantoprazole, saccharomyces boulardii, simeticon

194 ^cDrugs for respiratory tract: ambroxol, budesonide, codein, dextromethorphan, formoterol, hyoscine
195 butylbromide, ipratropium bromide, salbutamol, tiotropium bromide, tyloxapol

196 ^dOther drugs: amlodipine, bisoprolol, epoetin, levodopa/benserazid, levothyroxine, metoprolol,
197 naloxone, sage extract, sitagliptin, sodium bicarbonate, sodium polystyrene sulfonate

198

199 *Prevalence of off-label use in different therapeutic groups*

200 The five groups with the most application days were opioids (328 d; 14%), hypnotics
201 (228 d; 10%), respiratory tract (224 d; 10%), antiemetics (195 d; 8%), and non-opioid
202 analgesics (188 d; 8%), see Tab.1. The group with the highest rate of off-label
203 applications were anaesthetics, with ketamine as the only group representative. All
204 17 days of use were outside the license, as it was used exclusively in the non-
205 approved indication of pain. A likewise large number of uses beyond the license was
206 documented for antipsychotics (95 d; 89%). Of these, 68 application days were
207 related to non-licensed indications (80%). The drug mainly used in this group was
208 quetiapine with 52 application days and an off-label/in-label ratio of 96% (50 d). Of
209 these, 33 application days (66%) were for off-label indications like delirium or
210 depression and supported by scientific literature. Haloperidol (9d; 100%) and
211 levomepromazine (26d; 100%) were used less frequently, but only outside the
212 approved indication (both used for nausea).

213 Within the group of opioids, morphine was the drug most commonly used with
214 152/329 application days (46%). Of the 152 application days, 133 days were off-label
215 (88%); 101 days (81%) were for the off-label indication dyspnea and supported by

216 literature recommendations. The remaining 51 applications days (38%) were related
217 to a non-licensed use in combination with other drugs in the same syringe.

218 Antidepressants (156 d of all application days; 7%), corticosteroids (148 d of all
219 application days; 6%), drugs for anticoagulation (102 d of all application days, 4%),
220 diuretics (72 d of all application days; 3%) and anaesthetics (17d of all application
221 days; 0.7%) differed from all other groups as all uses beyond the license were solely
222 for off-label indications and not for other reasons. In the antidepressant group,
223 mirtazapine (112 d), trimipramine (7 d) and venlafaxin (14 d) summed up to a total of
224 133 days and 97% off-label/in-label-ratio. In the corticosteroid group, all off-label
225 administrations were related to dexamethasone (105 d off-label use; 8% off-label
226 use). Of these five drug groups, diuretics had a relatively low off-label/in-label-ratio
227 (33 d off-label use; 46%), and the off-label days were mainly caused by the use of
228 torasemide (26d) for a differing indication. Dexamethasone and torasemide were
229 both prescribed for edema, dexamethasone additionally for pain. Mirtazapine and
230 trimipramine were used for insomnia, mirtazapine additionally for pain. Venlafaxine
231 was used for pain and aspirin in atrial fibrillation. None of these indications were
232 supported by the literature specified above.

233 In addition to the drug groups, another 20 drugs (22% of all drugs used) were only
234 used off-label. Twelve drugs were always used in differing indications, s. fig 2 Other
235 drugs with 100% off-label application days were bisoprolol, levomethadone,
236 meropenem, simeticone, sitagliptin, budesonide/formoterol, thyme juice, and tilidine.

237 Figure 2 about here

238 *Drug relevance in palliative care*

239 The 93 drugs used during the observation period were stratified into groups
240 according to their relevance for palliative care pharmacotherapy (high, medium, low).
241 30 (32%) drugs were considered as highly relevant, e.g. ketamine, haloperidol,
242 hyoscine butylbromide, and morphine. The relevance is also reflected by the total
243 application days of this group. Of 1432/2352 (67%) application days attributable to
244 drugs in this group, 902 days (63%) were off-label. For 14 of these drugs some
245 evidence for off-label use could be identified in the literature screened. The type of
246 off-label use and underlying evidence is displayed in table 3.

247

248

	Type of off-label use (displayed in applications days)									Off-label indication	Underlying evidence
	Application days	Off-label use	Indication	Dose	Interval	Titration	Duration	Mode of Administration	Route		
Buprenorphine	4	-	-	-	-	-	-	-	-	-	-
Butylscopolamin	28	27	21	-	-	-	-	36	-	mostly noisy secretions	German Guideline, APM
Dexamethasone	134	105	105	-	-	-	-	-	8	mostly edema	German Guideline, APM
Dimenhydrinate	12	6	-	-	-	-	-	-	6	-	-
Domperidone	1	-	-	-	-	-	-	-	-	-	-
Fentanyl	33	21	21	-	-	-	-	-	-	dyspnea	German Guideline, APM
Granisetron	21	21	18	-	-	-	-	2	20	nausea/vomiting (not chemotherapy associated)	APM
Haloperidol	9	9	9	-	-	-	-	-	2	nausea	APM
Hydromorphone	75	49	22	-	-	-	-	25	-	dyspnea	German Guideline, APM
Ketamine	17	17	17	-	-	-	-	8	-	pain	APM
Lacosamide	23	5	-	-	-	5	-	-	-	-	-
Sodiumpicosulphate	55	-	-	-	-	-	-	-	-	-	-
Levetiracetam	49	20	-	-	-	3	-	12	13	-	-
Levomepromazin	26	26	26	-	-	-	-	4	15	nausea/vomiting	APM

e											miting	
Levomethadone	1	1	-	-	-	-	-	1	-	-	-	-
Lorazepam	35	6	-	-	2	-	-	4	-	-	-	-
Metoclopramide	101	65	-	6	-	-	35	44	4	-	-	-
Melperone	8	-	-	-	-	-	-	-	-	-	-	-
Metamizole (dipyrone)	174	48	-	-	-	-	-	96	13	-	-	-
Midazolam	61	61	61	-	-	-	-	58	22	agitation, anxiety	German Guideline, APM	-
Mirtazapine	112	108	108	-	-	-	-	-	-	insomnia, pain	APM	-
Morphine	152	133	101	-	-	-	-	51	-	dyspnea	German Guideline, APM	-
Movicol	69	-	-	-	-	-	-	-	-	-	-	-
Ondansetron	2	2	2	-	-	-	-	-	-	nausea/vomiting (not chemotherapy associated)	APM	-
Piritramid	59	36	11	18	-	-	-	22	-	dyspnea	German Guideline, APM	-
Pregabalin	102	6	0	6	-	-	-	-	-	-	-	-
Quetiapine	52	50	33	17	-	-	-	26	-	delirium, agitation	APM	-
Tapentadol	1	-	-	-	-	-	-	-	-	-	-	-
Tilidin	2	2	-	2	-	-	-	-	-	-	-	-
Venlafaxine	14	14	14	-	-	-	-	-	-	-	-	-

249 Table 3. Type of off-label use for drugs highly relevant in palliative care during the
250 study period (displayed in application days)

251

252 With decreasing relevance of the groups for symptom control, the total number of
253 application days as well as the off-label/in-label ratio dropped: the group of medium
254 relevant drugs (40; 43%; e.g. pantoprazole, enoxaparin) accounted for 714/2352
255 (30%) of all application days; of these 255/714 (36%) were off-label. The group with
256 the lowest relevance accounted for only 9% (210) of all application days with a total
257 of 83 (40%) off-label application days.

258

259 **Discussion**

260 Little is known about off-label drug use in palliative care in different national and
261 institutional circumstances. This article provides a first detailed evaluation of off-label
262 use on a palliative care unit in Germany. We aimed to get insights into off-label
263 prescribing and therefore critically evaluated not only the indication but also other
264 areas of off-label use, such as drug dose, dosing interval, route and mode of
265 administration. To our knowledge such an extensive assessment of off-label drug use
266 has not been published for adult palliative care previously.

267 Off-label use was common in this unit with more than half of all drug uses outside the
268 marketing authorisation. Compared to other studies, the frequency of off-label use
269 was rather high in our sample¹. This can partially be explained by the fact that we
270 evaluated off-label use not only with regard to indication but to six other aspects of
271 the approval (i.e. dose, mode of application, etc.). The large proportion of off-label
272 use regarding the indications was hardly surprising. Many drugs are not approved for
273 the relatively specific indications in palliative medicine. Still, compared to publications
274 from the UK (14.5%²) and the US (up to 35%¹⁸), the frequency of off-label use was
275 remarkably high. The extent to which the use deviated from the actual approval was
276 very heterogeneous. Midazolam, for example, is authorized for sedation in intensive
277 care but not in palliative medicine. In comparison, the established palliative care
278 indication of dyspnea for opioids is not even close to being covered by the approval
279 in Germany, although very well covered by scientific evidence^{19, 20}. In our study, the
280 application mode was the second most common cause for off-label use. The reason
281 for this was almost exclusively the non-approved mixing of different substances in a
282 syringe and the subsequent application as continuous infusion. Since data on the
283 compatibility of the mixtures used and on the benefit of a continuous infusion

284 compared to intermittent injections are only available to a very limited extent, this
285 practice must be critically questioned and discussed in more detail. A route of
286 administration beyond the approval only came in fourth place in our evaluation.
287 However, when considering subcutaneous administration alone, our assumptions of
288 more common off-label use were confirmed. These findings are consistent with other
289 studies evaluating subcutaneous administration in palliative care (62-85%^{2, 21}).

290 Among drugs and drug groups frequently used off-label were ketamine,
291 antipsychotics, antidepressants, drugs for gastrointestinal symptoms, corticosteroids
292 and opioids. These were frequently identified in other studies in the context of off-
293 label use and palliative care as well^{2, 18, 22}. Based on these findings it seems that
294 common symptoms in advanced disease like dyspnoea, nausea or vomiting either
295 lack authorized therapies or licensed alternatives are not used. Possible reasons for
296 the latter, however, cannot be determined due to the retrospective study design.

297 An important finding is the high number of overall off-label application days, the
298 proportion of off-label days in the group of “highly relevant” palliative care drugs, and
299 the decreasing number of overall and off-label application days with decreasing
300 relevance of a drug. This results underpins the high relevance of off-label use in
301 palliative medicine. However, this does not allow for conclusions on the justification
302 of off-label drug use in palliative medicine. Especially the lack of evidence to support
303 off-label use and the high proportion of off-label days without evidence need to be
304 noted. This proportion is rather high compared to other studies (3-11%^{2, 18}). Although
305 we have compared our data with two well-known and established
306 references^{14, 23}, this approach does only allow limited conclusions on the quality of
307 the underlying evidence.

308 We assessed off-label use with regard to every aspect of the marketing authorisation,
309 the relevance of drugs for palliative care and the availability of explicit literature
310 references. Data available so far still only allows limited insights into off-label
311 prescribing behaviour in different institutions and in different national contexts,
312 though. Reasons that led to a therapeutic decision cannot be illustrated. It is also not
313 clear what role patient-specific or infrastructural factors played in the treatment
314 selection. To be able to continue working with our and previous findings, it is
315 important to have the opportunity to compare off-label use in different institutions and
316 different countries. Such data can serve as a benchmark for quality assurance; they

317 can help to identify areas that seem to represent therapy standards but with no or
318 very little available evidence on the other. They can also be used to identify
319 therapeutic strategies that may be outdated by other approaches. Based on such
320 comparisons it would also be possible to develop quality indicators for off-label use in
321 palliative care. Our results demonstrate that there are multiple opportunities for
322 pharmacists to support off-label use of drugs in clinical routine, especially when
323 evaluating a treatment or possible treatment alternatives.

324 This study has several limitations. Data extraction was restricted to one month in one
325 palliative care unit. Therefore, data collection on off-label use from different palliative
326 care institutions in Germany is currently being prepared as a follow-up project.
327 Retrospective data collection relies on the quality of the documentation as wrong or
328 missing data cannot be replaced or completed. We were able to extract the required
329 data for all patients that were treated during the period analysed and, in most cases,
330 ambiguities could be resolved based on the patient records. The data presented here
331 is from 2017 and might be considered outdated. However, for a retrospective
332 evaluation of prescribing data, a time delay until the data is available should always
333 be expected. Furthermore an update and extension of the German Guideline on
334 Palliative Medicine for Patients with Incurable Cancer²⁴ has been published and its
335 influence on prescribing behaviour is not clear. It will therefore be interesting to
336 compare whether it had an impact on off-label prescribing behaviour.

337 Off label use is an integral part of palliative medicine. With very strict consideration,
338 which does not only focus on the indication, the extent may be even greater than
339 previously known. Off-label use should not be a routine but rather encourage to
340 question a therapy. At the same time, however, it must be possible to prescribe well-
341 established and scientifically sound therapies without justification if appropriate for an
342 individual patient. Ultimately, it is important to critically question the necessity of
343 every drug - whether inside or outside the marketing authorisation, for every patient.
344 As an important first step, the data presented here allow for a more precise
345 characterization of various aspects of off-label use in everyday clinical practice in
346 order to use this knowledge to derive concrete further measures for research and
347 clinical practice. As a follow-up to this pilot study, the next step will be to collect and
348 evaluate data on off-label use in various palliative care settings. These results will
349 then be used, in part, for quality assurance in the off-label drug use in palliative care.

350

351 **Conflict of interest statement**

352 The Authors declare that there are no competing interests. This project did not
353 receive funding.

354

355 **Acknowledgements**

356 The authors would like to thank Stefanie Büsel for assisting in the data extraction
357 process.

358

References

1. Hagemann V, Bausewein C, Remi C. Drug use beyond the licence in palliative care: A systematic review and narrative synthesis. *Palliative Medicine*. 2019;33(6):650-62.
2. Atkinson C, Kirkham S. Unlicensed uses for medication in a palliative care unit. *Palliative Medicine*. 1999;13:145–52.
3. Todd J, Davies A. Use of unlicensed medication in palliative medicine. *Palliative Medicine*. 1999;13:466.
4. García-López I, Cuervas-Mons Vendrell M, Martín Romero I, de Noriega I, Benedí González J, Martino-Alba R. Off-Label and Unlicensed Drugs in Pediatric Palliative Care: A Prospective Observational Study. *Journal of pain and symptom management*. 2020.
5. FDA. Understanding Unapproved Use of Approved Drugs "Off Label" [cited 2019 Feb 05]. 2018 [updated 02/05/201808/02/2019]. Available from: <https://www.fda.gov/forpatients/other/offlabel/default.htm>.
6. Aronson JK, Ferner RE. Unlicensed and off-label uses of medicines: definitions and clarification of terminology. *Br J Clin Pharmacol*. 2017;83(12):2615-25.
7. Johnson MJ, Currow DC. Opioids for breathlessness: a narrative review. *BMJ supportive & palliative care*. 2020;10(3):287-95.
8. Gremaud G, Zulian GB. Indications and Limitations of Intravenous and Subcutaneous Midazolam in a Palliative Care Center. *Journal of pain and symptom management*. 1998;15(6):331-3.
9. Amesbury BDW, Dunphy KP. The use of subcutaneous midazolam in the home care setting. *Palliative Medicine*. 1989;3:299–301.
10. Eguale T, Buckeridge DL, Verma A, Winslade NE, Benedetti A, Hanley JA, et al. Association of Off-label Drug Use and Adverse Drug Events in an Adult Population. *JAMA internal medicine*. 2016;176(1):55-63.
11. Hagemann V, Bausewein C, Rémi C. Off-label-prescriptions in daily clinical practice – a cross-sectional national survey of palliative medicine physicians. *Progress in Palliative Care*. 2019:1-6.
12. Nationale Akademie der Wissenschaften Leopoldina und Union der deutschen Akademien der Wissenschaften. Palliativversorgung in Deutschland – Perspektiven

für Praxis und Forschung. 2015. Available from:

http://www.leopoldina.org/uploads/tx_leopublication/2015_Palliativversorgung_LF_D_E.pdf.

13. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *International journal of surgery (London, England)*. 2014;12(12):1495-9.

14. Leitlinienprogramm Onkologie. S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Tumorerkrankung 2015 [Available from:

http://leitlinienprogramm-onkologie.de/uploads/tx_sbdownloader/LL_Palliativmedizin_Langversion_1_1.pdf.

15. Rémi C, Bausewein C, Twycross R, Wilcock A, Howard P, editors.

Arzneimitteltherapie in der Palliativmedizin. 2 ed. München: Urban & Fischer; 2015.

16. Essential medicine in palliative care: executive summary [Internet]. 2013 [cited 14.08.2015]. Available from:

http://www.who.int/selection_medicines/committees/expert/19/applications/PalliativeCare_8_A_R.pdf.

17. Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, et al. Drugs in palliative care: results from a representative survey in Germany. *Palliative Medicine*. 2004;18:100-7.

18. Kwon JH, Kim MJ, Bruera S, Park M, Bruera E, Hui D. Off-label Medication Use in the Inpatient Palliative Care Unit. *J Pain Symptom Manage*. 2017.

19. Ekstrom M, Bajwah S, Bland JM, Currow DC, Hussain J, Johnson MJ. One evidence base; three stories: do opioids relieve chronic breathlessness? *Thorax*. 2017;73(1):88-90.

20. Barnes H, McDonald J, Smallwood N, Manser R. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. *Cochrane Database Syst Rev*. 2016;3:Cd011008.

21. Toscani F, Di Giulio P, Campi R, Pellerin I, De Luca A, Casale G. Off-label prescriptions in Italian hospices: a national survey. *J Pain Symptom Manage*. 2009;38(3):365-71.

22. Culshaw J, Kendall D, Wilcock A. Off-label prescribing in palliative care: a survey of independent prescribers. *Palliative Medicine*. 2013;27(4):314-9.

23. Rémi C, Bausewein C, Twycross R, Wilcock A, Howard P, editors.
Arzneimitteltherapie in der Palliativmedizin. 3 ed. München: Elsevier Urban & Fischer; 2018.
24. Leitlinienprogramm Onkologie. Erweiterte S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung. Langversion 2.0–August 2019
AWMF-Registernummer: 128/001-OL 2019 [Available from:
https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Palliativmedizin/Version_2/LL_Palliativmedizin_2.0_Langversion.pdf].




Fig. 1 Frequency of off-label application days by type of off-label use

total number of drug applications days (in-label and off-label): 2,352

*off-label uses could occur in more than one category resulting in a higher total number of off-label uses than application days.




Fig. 2 Applications days of drugs solely used off-label

Only drugs that have solely been used outside the approved indication are listed.